

Please type a plus sign (+) inside this box.



Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/687,706
			Filing Date	October 20, 2003
			First Named Inventor	Loscalzo
			Group Art Unit	1657
			Examiner Name	K.C. Srivastava
			Attorney Docket Number	102258.170US2
Sheet	2	of	5	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Dupuis, Cardiovascular Drugs and Therapy, 8(3):501-507 (1994).	
		Cohn et al, The New England Journal of Medicine, 325(5):303-310 (1991).	
		Cohn et al, The New England Journal of Medicine, 314(24):1547-1552 (1986).	
		Carson et al, Circulation, Supplement I, 92(8):I31-I32, Abstract No. 0145 (1995).	
		Francis et al, Circulation, Supplement VI, 87(6):VI40-VI48 (1993).	
		Pierpont et al, Chest, 73(1):8-13 (1978).	
		Massie et al, The American Journal of Cardiology, 40:794-801 (1977).	
		Kaplan et al, Annals of Internal Medicine, 84:639-645 (1976).	
		Bauer et al, Circulation, 84(1):35-39 (1991).	
		The SOLVD Investigators, The New England Journal of Medicine, 327(10):685-691 (1992).	
		Ziesche et al, Circulation, 87(6):VI56-VI64 (1993).	

Examiner Signature	/Kailash Srivastava/	Date Considered	04/12/2008
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.S./

Please type a plus sign (+) inside this box.



PTO/SB/08B (10-96)
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/687,706
			Filing Date	October 20, 2003
			First Named Inventor	Loscalzo
			Group Art Unit	1657
			Examiner Name	K.C. Srivastava
			Attorney Docket Number	102258.170US2
Sheet	3	of	5	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Rector et al, Circulation, 87(6):VI71-VI77 (1993).	
		Carson et al, Journal of Cardiac Failure, 5(3):178-187 (September 10, 1999).	
		Dries et al, The New England Journal of Medicine, 340(8):609-616 (February 25, 1999).	
		Freedman et al, Drugs, 54(Supp. 3):41-50 (1997).	
		Sherman et al, Cardiologia, 42(2):177-187 (1997).	
		Biegelson et al, Coronary Artery Disease, 10-241-256 (1999).	
		Rudd et al, Am. J. Physiol., 277(46):H732-H739 (1999).	
		Hammerman et al, Am. J. Physiol., 277(46):H1579-H1592 (1999).	
		Loscalzo et al, Transactions of the American and Climatological Ass., 111:158-163 (2000).	
		Burnier et al, Hypertension, 22(3):339-347 (September 1993).	
		von Lutterotti et al, American Journal of Hypertension, 4(4, Part 2):346S-349S (1991).	

Examiner Signature	/Kailash Srivastava/	Date Considered	04/13/2008
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.S./

Please type a plus sign (+) inside this box



PTO/SB/08B (10-96)

Valid for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/687,706
		Filing Date	October 20, 2003
		First Named Inventor	Loscalzo
		Group Art Unit	1657
		Examiner Name	K.C. Srivastava
		Attorney Docket Number	102258.170US2
Sheet	4	of	5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Johnson, Clinical Pharmacy, Vol. 5, pages 536 and 541 (1986).	
		Massie et al, Br. Heart J., 45:376-384 (1981).	
		Turner et al, The American Journal of Cardiology, 47:910-916 (1981).	
		Massie et al, Circulation, 63(3):658-664 (1981).	
		Nelson et al, Journal of Cardiovascular Pharmacology, 5(4):574-579 (1983).	
		Leier et al, Circulation, 63(1):102-109 (1981).	
		Wilson et al, The American Journal of Medicine, 71:627-633 (1981).	
		Biddle et al, J. Clin. Pharmacol., 21:343-350 (1981).	
		Magorien et al, Clinical Research, 27(4):A617 (1979).	
		Turner et al, Clinical Research, 29(2):246A (1981).	
		Hibiya et al, Japanese Circulation Journal, 45:966 (Abstract No. 338) (1981).	

Examiner Signature	/Kailash Srivastava/	Date Considered	04/13/2008
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.S./

Please type a plus sign (+) inside this box



PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/687,706
		Filing Date	October 20, 2003
		First Named Inventor	Loscalzo
		Group Art Unit	1657
		Examiner Name	K.C. Srivastava
		Attorney Docket Number	102258.170US2
Sheet	5	of	5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Franciosa et al, Circulation, 59(6):1085-1091 (1979).	
		Lanas et al, Rev. Med. Chile, 107:926-930 (1979).	
		Usdin et al, Coeur, 10(1):119-128 (1979).	

Examiner Signature	/Kailash Srivastava/	Date Considered	04/13/2008
-----------------------	----------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.S./